SALT Trial: Steroids after Laser Trabeculoplasty: Impact of Short-Term Anti-inflammatory Treatment on Selective Laser Trabeculoplasty Efficacy.


Journal

Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443

Informations de publication

Date de publication:
11 2019
Historique:
received: 12 11 2018
revised: 25 04 2019
accepted: 28 05 2019
pubmed: 25 8 2019
medline: 14 3 2020
entrez: 25 8 2019
Statut: ppublish

Résumé

This study examined whether short-term use of topical nonsteroidal anti-inflammatory drug (NSAID) or steroid therapy affected the efficacy of selective laser trabeculoplasty (SLT). Double-masked, randomized, placebo-controlled, dual-center, multisurgeon trial. Patients older than 18 years with intraocular pressure (IOP) of more than 18 mmHg for whom the clinician decided SLT was the appropriately indicated therapy were randomized to 1 of 3 groups in a ratio of 1:1:1 as follows: ketorolac 0.5%, prednisolone 1%, or saline tears. After SLT, patients randomized into each group were instructed to use an unmarked drop 4 times daily starting the day of SLT and continuing for 4 additional days. The Kruskal-Wallis test and Wilcoxon rank-sum test were used for continuous variables when comparing 2 or 3 treatment groups, respectively. The Fisher exact test was used for categorical variables. The primary outcome of this study was IOP at 12 weeks. Secondary outcome measures included IOP at 1 and 6 weeks, patient-reported pain, and detectable anterior chamber inflammation. Ninety-six eyes of 85 patients fit inclusion criteria and were enrolled between the 2 sites. The NSAID, steroid, and placebo groups were similar in baseline demographics and baseline IOP (mean, 23.3±3.9 mmHg; P = 0.57). There was no statistically significant difference in IOP decrease among groups at week 6. Both the NSAID and steroid groups showed a statistically significantly greater decrease in IOP at week 12 compared with the placebo group (mean, -6.2±3.1 mmHg, -5.2±2.7 mmHg, and -3±4.3 mmHg, respectively; P = 0.02 [analysis of variance] and P = 0.002 [t test] for NSAID vs. placebo groups; P = 0.02 for steroid vs. placebo groups). Significantly better IOP reduction at 12 weeks was measured in eyes treated with steroid or NSAID drops after SLT. Short-term postoperative use of NSAID or steroid drops may improve IOP reduction after SLT. Longer-term follow-up studies are indicated.

Identifiants

pubmed: 31444008
pii: S0161-6420(18)32934-8
doi: 10.1016/j.ophtha.2019.05.032
pmc: PMC6810843
mid: NIHMS1538077
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Glucocorticoids 0
Ophthalmic Solutions 0
Prednisolone 9PHQ9Y1OLM
Ketorolac YZI5105V0L

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1511-1516

Subventions

Organisme : NEI NIH HHS
ID : P30 EY022589
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Published by Elsevier Inc.

Références

Arch Ophthalmol. 1988 Apr;106(4):544-7
pubmed: 3355425
Br J Ophthalmol. 2005 Sep;89(9):1157-60
pubmed: 16113372
Br J Ophthalmol. 1999 Jun;83(6):718-22
pubmed: 10340983
Arch Ophthalmol. 1993 Apr;111(4):481-3
pubmed: 8470978
Ophthalmol Ther. 2013 Dec;2(2):113-20
pubmed: 25135811
Can J Ophthalmol. 2007 Oct;42(5):715-9
pubmed: 17891199
Arch Ophthalmol. 1979 Feb;97(2):319-22
pubmed: 575877
Am J Ophthalmol. 1996 Sep;122(3):349-54
pubmed: 8794707
Br J Ophthalmol. 1999 Jan;83(1):29-32
pubmed: 10209430
Trans Am Ophthalmol Soc. 1983;81:325-32
pubmed: 6676975
Arch Ophthalmol. 1989 Apr;107(4):572-6
pubmed: 2705927
Ophthalmologica. 2004 Jan-Feb;218(1):20-5
pubmed: 14688431
Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):100-3
pubmed: 20128578
Exp Eye Res. 1995 Apr;60(4):359-71
pubmed: 7789416
Arch Ophthalmol. 1985 Oct;103(10):1546-52
pubmed: 4051857
Eur J Ophthalmol. 2002 Jul-Aug;12(4):287-92
pubmed: 12219998
Arch Ophthalmol. 1983 Mar;101(3):382-4
pubmed: 6830487
Graefes Arch Clin Exp Ophthalmol. 1995 Sep;233(9):559-62
pubmed: 8543206
BMC Ophthalmol. 2008 Oct 21;8:20
pubmed: 18939999
Br J Ophthalmol. 2006 Dec;90(12):1490-4
pubmed: 16899528
Clin Exp Ophthalmol. 2004 Aug;32(4):368-72
pubmed: 15281969
Ophthalmol Clin North Am. 2005 Sep;18(3):409-19, vi
pubmed: 16054998
Ophthalmology. 2014 Dec;121(12):2356-61
pubmed: 25234015
Curr Opin Ophthalmol. 2007 Mar;18(2):140-5
pubmed: 17301616
Br J Ophthalmol. 2005 Nov;89(11):1413-7
pubmed: 16234442
Eur J Ophthalmol. 2006 Jan-Feb;16(1):100-4
pubmed: 16496252
J Ophthalmol. 2012;2012:642869
pubmed: 22900148
Ophthalmology. 1984 Sep;91(9):1005-10
pubmed: 6493712
Invest Ophthalmol Vis Sci. 2000 Feb;41(2):422-30
pubmed: 10670472
Ophthalmologica. 2001 Jul-Aug;215(4):267-70
pubmed: 11399933
Am J Ophthalmol. 2005 Sep;140(3):524-5
pubmed: 16139003
J Glaucoma. 2017 Feb;26(2):e22-e29
pubmed: 27552500

Auteurs

Sylvia L Groth (SL)

Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California.

Eiyass Albeiruti (E)

Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Mariana Nunez (M)

Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California; Bascom Palmer Eye Institute, University of Miami, Miami, Florida; Shiley Eye Institute, University of California, San Diego, La Jolla, California.

Roman Fajardo (R)

Shiley Eye Institute, University of California, San Diego, La Jolla, California.

Lucie Sharpsten (L)

Shiley Eye Institute, University of California, San Diego, La Jolla, California.

Nils Loewen (N)

Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Joel S Schuman (JS)

Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Jeffrey L Goldberg (JL)

Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California; Bascom Palmer Eye Institute, University of Miami, Miami, Florida; Shiley Eye Institute, University of California, San Diego, La Jolla, California. Electronic address: eye-chair@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH